Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04553757 · ClinicalTrials.gov registry record
Seizure Control as a New Metric in Assessing Efficacy of Tumor Treatment in Patients With Low Grade Glioma
A clinical trial of Low Grade Glioma and Brain Neoplasm, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT04553757 is a study of Low Grade Glioma and Brain Neoplasm that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 100 participants, roughly in line with the 110-participant average among 23 other Low Grade Glioma trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT04553757, a study of Low Grade Glioma and Brain Neoplasm, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This study investigates how seizures can vary over time with changes in low grade gliomas and its treatments. This study may help doctors find symptoms or triggers of seizures earlier than normal, and ultimately earlier care or treatment for seizures.
Conditions Studied
Interventions
- OTHER Survey Administration
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2020-07-08 |
| Est. Completion | 2025-12-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04553757
The ClinicalTrials.gov registry entry for NCT04553757 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 110-participant average among 23 other Low Grade Glioma trials with a reported enrollment target. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Low Grade Glioma appearing as the primary indexed condition, and to 1 intervention - of which Survey Administration is the first listed.
NCT04553757 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04553757 about?
NCT04553757 is a clinical study titled "Seizure Control as a New Metric in Assessing Efficacy of Tumor Treatment in Patients With Low Grade Glioma". This study investigates how seizures can vary over time with changes in low grade gliomas and its treatments. This study may help doctors find symptoms or triggers of seizures earlier than normal, and ultimately earlier care or treatment for seizures.
What is the current status of trial NCT04553757?
This trial is currently active not recruiting. The enrollment target is 100 participants. The study started on 2020-07-08. Estimated completion is 2025-12-30.
What conditions does trial NCT04553757 study?
This clinical trial studies the following conditions: Low Grade Glioma, Brain Neoplasm, Seizure Disorder.
What interventions are being tested in trial NCT04553757?
The interventions under investigation include: Survey Administration (OTHER).
Who is sponsoring clinical trial NCT04553757?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04553757 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Low Grade Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Vaccine Trial for Low Grade Gliomas
RECRUITING · Phase 2
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
RECRUITING · Phase 1
-
Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial
RECRUITING · Phase 2
-
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
RECRUITING · Phase 3
-
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.